SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer

摘要: The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles (area under the curve (AUC) 7) followed by 100 mg m(-2) (arm A, n=51) or 60 with irinotecan 200 B, n=49). Neither arm met formal criterion an eight-cycle completion rate that statistically greater than 60% A 71% (90% confidence interval (CI) 58-81%; P=0.079; B 67% CI 55-78%; P=0.184)). Median-dose intensities >85% planned dose all agents. In arms 15.6 12.2% patients, respectively, withdrew owing treatment-related toxicity. Grade 3-4 sensory neurotoxicity more common in (1.9 vs 0%) grade diarrhoea (0.6 3.5%). Of radiologically evaluable disease at baseline, 50 48% responded therapy respectively; median 17.1 months' follow-up, progression-free survival 15.9 months, respectively. Although both just failed meet statistical criteria, observed rates around 70% reasonable. addition generally well tolerated although associated increased gastrointestinal Further exploratory studies topoisomerase-I inhibitors this setting may be warranted.